 |
Contact
| Lab: | Prof. Dr. Heike Pahl |
| Department: | Professor, Chair Section of Molecular Hematology University Medical Center |
| Address: | Breisacher Str. 66 79106 Freiburg Germany |
| Phone: | +49 761 270 63400 |
| E-mail: | This e-mail address is being protected from spambots. You need JavaScript enabled to view it |
| Lab homepage: | www.uniklinik-freiburg.de/medizin1/forschung/experimentelle-forschung/sektion-molekulare-haematologie.html |
| PhD positions available: | YES |
| Research Area: | Molecular Medicine |
| Research Interests: | -Molecular markers in Myeloproliferative Disorders -The role of transcription factor NF-E2 -Molecular etiology of NF-E2 and PRV-1 Overexpression in MPD -Molecular heterogeneity in Essential Thrombycythemia -Mouse models of myeloproliferative disorders |
CV
| Education & Training: | 1985-1987: Wellesley College, Wellesley, MA, U. S. A. - Majors: Biochemistry and Economics May 29, 1987: B.A., Wellesley College 1987-1992: Harvard University, Cambridge, MA, U. S. A. June 7, 1990: M.A., Harvard University July 14, 1992: Ph. D., Harvard University. Thesis: "Cloning and Characterization of the CD11b Promoter." July 10, 1997: Habilitation at the Medical School of the Albert-Ludwigs-Universität Freiburg |
| Employment & Experience: | 1992-1995: Postdoctoral Fellow at the Laboratory for Molecular Biology, Genecenter, of the Ludwig-Maximilians-Universität München and at the Institute for Biochemistry and Molecular Biology of the Albert-Ludwigs-Universität Freiburg in the laboratory of Prof. Dr. Patrick Baeuerle 1995-1997: Assistant Professor, Institute for Biochemistry and Molecular Biology of the Albert-Ludwigs-Universität 1998: Heisenberg-Stipend of the “Deutsche Forschungsgemeinschaft” (German equivalent of the NSF) since 1998: Professor (tenured), University Medical Center of the Albert-Ludwigs-Universität Freiburg, Chair of the Section of Molecular Hematology |
| Scientific Activities: | Editorial Board: Blood Section Editor „Experimental Hematology“: Annals of Hematology Editorial Board:Current Signal Transduction Therapy Editorial Board: The European Journal of Clinical & Medical Oncology Scientific Board: Else Kröner-Fresenius-Stiftung Co-Organisation of the First International Workshop on Myeloproliferative Disorders: “Towards an Understanding of the Molecular Basis of Myeloproliferative Disorders”, Benediktiner Abtei, Frauenchiemsee, 23.-28. September 2000 Organisation of the Como Conference on Myeloproliferative Disorders. „The Molecular Pathogenesis and Genetics of Myeloproliferative Diseases” 13. - 17. Loveno di Menaggio, Italien, 13.-16. September 2002 Co-Organisation of the European School of Haematology Conferences: „Myeloproliferative Disorders: Molecular Pathogenesis and Therapy“, 2004, 2006, 2008, 2010, 2012, 2014 |
Honors
| Honors and Awards: | 1987 Phi Beta Kappa |
Publications
| Selected Publications: | Jutzi JS, Pahl HL (2015) The Hen or the Egg: Inflammatory Aspects of Murine MPN Models, Med. Inflamm. In press. Koschmieder S, Mughal TI, Hasselbalch HC, Barosi G, Valent P, Kiladjian JJ, Jeryczynski G, Gisslinger H, Jutzi JS, Pahl HL, Hehlmann R, Maria Vannucchi A, Cervantes F, Silver RT, Barbui T (2016) Myeloproliferative neoplasms and inflammation: whether to target the malignant clone or the inflammatory process or both. Leukemia, in press. Jutzi JS, Bogeska R, Nikoloski G, Schmid CA, Seeger TS, Stegelmann F, Schwemmers S, Gründer A, Peeken J, Gothwal M, Wehrle J, Aumann K, Hamdi K, Dierks, C, Wang W, Döhner K, Jansen JH, Pahl HL (2013) MPN patients harbor recurrent truncating mutations in transcription factor NF-E2, J. Ex. Med, 210: 1003 - 1019. Abstract Kaufmann KB, Gründer A, Hadlich T, Wehrle J, Gothwal M, Bogeska R, Seeger TS, Kayer S, Pham KB, Jutzi JS, Ganzenmüller L, Steinemann D, Schlegelberger B, Wagner JM, Jung M, Will B, Steidl U, Aumann K, Werner M, Günther T, Schüle R, Rambaldi A, Pahl HL , (2012) Overexpression of transcription factor NF-E2: a novel murine model of myeloproliferative neoplasms. J. Exp. Med, 209 (1): 35 - 50. Abstract Wang W, Schwemmers S, Hexner EO, Pahl HL (2010) AML1 is overexpressed in patients with myeloproliferative neoplasms and mediates JAK2V617F-independent overexpression of NF-E2. Blood. (2010) 116(2):254-66. Epub 2010 Mar 25. Abstract Jones AV, Chase A, Silver RT, Oscier D, Zoi K, Wang YL, Cario H, Pahl HL, Reiter A, Grand F, Cross NCP (2009) JAK2 haplotype is a major risk factor for the development of myeloproliferative neoplasms, Nat Genet. (2009) 41(4):446-9. Epub 2009 Mar 15. Abstract Schwemmers S, Will B, Waller CF, Abdulkarim K, Johansson P, Andreasson B, Pahl HL (2007) JAK2V617F-negative ET Patients do not display constitutively active JAK/STAT signaling. Exp. Hematol, 35: 1695 – 1703. Abstract Goerttler PS, Steimle C, März E, Johansson PL, Andreasson B, Griesshammer M, Gisslinger H, Heimpel H, Pahl HL (2005) The Jak2V617F mutation, PRV-1 overexpression and EEC formation define a similar cohort of MPD patients. Blood, 106: 2862-2864. Abstract |
SGBM PhD students
| SGBM PhD students: |
Alumni Track 1: Jonas Jutzi (MD/PhD, 01/2015 - 07/2018)
Sven Schwemmers (09/2006 - 08/2010) |
